Past CABs and Success Stories
Based on the proven ECAB model implemented by the HIV patient community and EATG for more than a decade, the first CML-CAB was held in May 2016. Since then, we have carried out 14 CML Community Advisory Boards in 24 sessions (2016-2024).
14 CML-CABs in 24 sessions from 2016-2024
Please click on the links below to access the executive summaries of each the respective CAB meetings
| Date | Company CAB sessions | CAB Training sessions |
| 09/2024 | Novartis | Access and region specific issues around Asciminib |
| 06/2023 | 2nd Academic CML-CAB | |
| 02/2021 | Novartis | Access to cancer treatment & value proposition |
| 10/2020 | 1st Academic CML-CAB | CML Cure Academy: preparatory workshops and crash courses |
| 07/2020 | Incyte/Takeda | |
| 11/2019 | Novartis (+ Global President Oncol.) | |
| 5/2019 | Novartis | CML Horizons 2019 |
| 3/2019 | Pfizer Incyte Takeda | Strategic priority setting on CABs |
| 11/2018 | Novartis (+ CEO) | |
| 5/2018 | Novartis Pfizer Incyte | PRO & QoL instruments |
| 11/2017 | Novartis Incyte/Takeda | Collaboration with industry |
| 5/2017 | Novartis BMS Pfizer Incyte | CML Horizons 2017 |
| 2/2017 | Novartis Takeda/Incyte Ariad | CABs as an advocacy tool |
| 5/2016 | Novartis Pfizer | Drug development process and CML research |
Success Stories
With all our CABs, we make sure to have engaging conversations and come away with a set of points that we would like the companies to work on. Over the last CAB engagements, we have achieved:
- Novartis improved the patient experience and removed potential barriers to clinical trial participation with the help of CML AN: Listening to the CML patient community | Novartis